top of page

PROJECT STRUCTURE

 

The coordination of the NOSEVAC project is assured by the Coordinator (EVI) assisted by the Management Team (EVI) and the project General Assembly (GA). To increase the chance of success towards the set objectives, i.e., the development of a safe and effective vaccine to prevent URT pathogens, the consortium is supported by a Scientific and Ethics Advisory Committee (SEAC) that will provide strategic inputs into scientific-technical, public health and ethical issues.

NOSEVAC organisational structure includes three types of consortium bodies: strategic (General Assembly), implementation (Steering Committee, Project Management Team, Work Package Leaders and co-Leaders) and advisory (Scientific and Ethics Advisory Committee) bodies.

Covid 19

SEAC

Independent experts from relevant scientific fields that assist and facilitate the decisions made by the PSC and Coordinator.

Coordinator

European Vaccine Initiative

(EVI)

WPLs

Responsible for the detailed planning, implementation and oversight of individual work packages, reporting to PSC and the Coordinator 

PROJECT COORDINATOR:

Prof. Ole F. Olesen, European Vaccine Initiative (EVI)

 

SCIENTIFIC AND ETHICS ADVISORY COMMITTEE

The Scientific and Ethics Advisory Committee (SEAC) is composed of renowned scientists from the vaccine R&D field and experts in ethics, and social sciences and humanities. Additionally, Internal Ethics Advisors were appointed to oversee the implementation of the ethical concerns involved in this research.

SEAC Members:

  1. Prof. Isabelle Bekeredjian-Ding >

  2. Dr Martina Ochs >

  3. Prof. Gianni Pozzi >

  4. Prof. Jocelyn Raude >

 

Internal Ethics Advisor:

Prof. Ali Haradi

Prof. Jean Claude Sirard

 
Science

WORK PACKAGES

The NOSEVAC work plan is organised into 7 complementary work packages (WPs) and 34 tasks. See below to find more information about each WP in detail.

Work packages

Objectives

WP 1

Discovery of pneumococcal and pertussis antigens specific for nasal colonisation  

Leader: Jan-Willem Veening University of Lausanne, Switzerland. 
Co-leader:  Loic Coutte, Institut Pasteur Lille, France

 

Identify and produce specific conserved proteins required for bacterial colonisation of the upper respiratory tract as new vaccine antigens. 

WP 2

Innovative formulations for RNA- and protein-based viral and bacterial nasal vaccines 

Leader: Noemi Stefania Csaba University of Santiago de Compostela, Spain
Co-leader: Youlia Serikova, Quantoom. Belgium

 

Develop constructs and formulations for optimal stability, adhesion, deposition and retention in nasal mucosa of mRNA-, saRNA-, and protein-based vaccines, address bottlenecks in the production of RNA vaccines.

WP 3

In vitro activity of nasal vaccines in human cell-based systems 

Leader: Eliana Coccia Istituto Superiore di Sanità, Italy.
Co-leader: Samuel Constant, Epithelix, Switzerland

 

Evaluate the response induced by nasal vaccine candidates in vitro in human primary nasal and immune cell model to select the optimal formulation. 

WP 4

Preclinical evaluation of nasal vaccines efficacy in animal models 

Leader: Nathalie Mielcarek, Institut Pasteur Lille, France
Co-leader: Sander Herfst and Rory de Vries, ErasmusMC, The Netherlands

 

Identify key effectors of nasal and systemic, innate and adaptive immune responses; Assess vaccines’ protective efficacy in models of nasal colonisation and/or transmission and disease. 

WP 5

Profiling of nasal human immune response to infection and vaccination 

Leader: Daniela Ferreira, University of Oxford, UK.
Co-leader: Arnaud Didierlaurent, University of Geneva, Switzerland

 

Evaluation of immune response in the upper respiratory tract to define novel biomarkers of infection and correlates of protection in infected or vaccinated individuals.

WP 6

Ethical and psychological aspects of nasal vaccination 

Leader: Delphine Grynberg, University of Lille, France.
Co-leader: Jean-Claude Sirard, Institut Pasteur Lille, France

 

Ensure that ethics requirements are considered, applied, and implemented at all steps of NOSEVAC; Assess the acceptability of nasal vaccines in the general population and among clinicians who administrate vaccines in countries where nasal vaccines are available (UK) or not (France, Switzerland). 

WP 7

Management, communication, dissemination and exploitation

Leader: Monika Ślęzak, European Vaccine Initiative, Germany

 

Set up an effective management framework to ensure that NOSEVAC progresses towards its planned objectives in line with contractual commitments.

WP 8

Mathematical modelling of bioprocesses involved in the respiratory tract colonisation and nasal vaccines

Leader: Erida Gjini, Instituto Superior Técnico para a Investigação e Desenvolvimento, Portugal

 

Developing mathematical and quantitative modelling platforms for nasal vaccine research to help enhance our understanding on approaches for prevention and reduction of nasal colonisation of respiratory pathogens.

bottom of page